Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Terminated 4Recruiting 4Active not recruiting 4Withdrawn 3Unknown 1Suspended 1Not yet recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Neoplasms 8Pancreatic Neoplasms 4Myelodysplastic Syndromes 3Melanoma 3Leukemia, Myeloid, Acute 3Leukemia 3Glioblastoma 3Carcinoma, Non-Small-Cell Lung 3Carcinoma, Hepatocellular 3Stomach Neoplasms 2Recurrence 2Multiple Myeloma 2Lymphoma, T-Cell 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma 2Lung Neoplasms 2Colorectal Neoplasms 2Breast Neoplasms 2Vaginitis 1Uterine Cervical Neoplasms 1Tongue Neoplasms 1Solid Tumors 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Rectal Neoplasms 1Prostatic Neoplasms 1Primary Myelofibrosis 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1

Interventions

Monatide (IMS 3015) 1Biological Assay 1ALT-803 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Suspended × Neoplasm, Residual × Clear all
NCT05642195 2026-06-05

Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer

National Institutes of Health Clinical Center (CC)

Phase 1/2 Suspended
30 enrolled
Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡